CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL
✉ Email this page to a colleague
All Clinical Trials for Olmesartan Medoxomil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00134160 ↗ | OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study | Completed | Japan Heart Foundation | Phase 4 | 2005-08-01 | The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone. |
| NCT00134160 ↗ | OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study | Completed | OSCAR Study | Phase 4 | 2005-08-01 | The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone. |
| NCT00139698 ↗ | Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension | Completed | Pfizer | Phase 3 | 2005-09-01 | Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension |
| NCT00141453 ↗ | ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial | Completed | Daiichi Sankyo Co., Ltd. | Phase 3 | 2003-04-01 | The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease. |
| NCT00151775 ↗ | Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure | Completed | Daiichi Sankyo Inc. | Phase 2/Phase 3 | 2005-05-01 | This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks. |
| NCT00151775 ↗ | Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure | Completed | Daiichi Sankyo, Inc. | Phase 2/Phase 3 | 2005-05-01 | This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks. |
| NCT00151814 ↗ | Olmesartan Pediatric Pharmacokinetic (PK) Study | Completed | Daiichi Sankyo Inc. | Phase 1 | 2005-09-01 | Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Olmesartan Medoxomil
Condition Name
Clinical Trial Locations for Olmesartan Medoxomil
Trials by Country
Clinical Trial Progress for Olmesartan Medoxomil
Clinical Trial Phase
Clinical Trial Sponsors for Olmesartan Medoxomil
Sponsor Name
